You just read:

Shionogi Presents Results from a Phase 2 Proof-of-Concept Clinical Trial and Non-Clinical Studies of S-033188, a Novel Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza

News provided by

Shionogi & Co., Ltd.

28 Aug, 2016, 21:00 ET